紐約大學(xué)研究員獲美國(guó)國(guó)立衛(wèi)生研究院撥款，優(yōu)化CAR-T細(xì)胞癌治療!
2023-09-22 12:51:56 來(lái)源：中國(guó)教育在線
紐約大學(xué)研究員獲美國(guó)國(guó)立衛(wèi)生研究院撥款，優(yōu)化CAR-T細(xì)胞癌治療!，相信這個(gè)問(wèn)題是許多正在準(zhǔn)備留學(xué)的同學(xué)關(guān)心的一個(gè)問(wèn)題，那么下面小編就來(lái)和大家說(shuō)一說(shuō)，感興趣的您趕緊往下了解吧。
紐約大學(xué)研究員獲美國(guó)國(guó)立衛(wèi)生研究院（National Institutes of Health）撥款，優(yōu)化CAR-T細(xì)胞癌治療
BROOKLYN, New York, Monday, October 28, 2019 –Weiqiang Chen, assistant professor of biomedical engineering and mechanical and aerospace engineering at the NYU Tandon School of Engineering, has been awarded the Maximizing Investigators’ Research Award (R35) from the National Institute of General Medical Sciences, a pision of the National Institutes of Health (NIH). The five-year, $1.7 million grant will support Chen’s lab’s efforts to devise engineering-based methods for understanding and improving the efficacy of immunotherapy treatment for cancer.
2019年10月28日，星期一，紐約布魯克林區(qū)——紐約大學(xué)TANDUN工程學(xué)院生物醫(yī)學(xué)工程和機(jī)械與航空工程助理教授Weiqiang Chen被授予國(guó)立醫(yī)學(xué)研究所最大的研究者研究獎(jiǎng)（R35），美國(guó)國(guó)立衛(wèi)生研究院的一個(gè)部門。這項(xiàng)為期5年、170萬(wàn)美元的撥款將支持陳的實(shí)驗(yàn)室努力設(shè)計(jì)基于工程的方法，以了解和提高癌癥免疫治療的療效。
Chen, who heads NYU Tandon’s Applied Micro-Bioengineering Laboratory, explained that the grant will advance three key areas of interdisciplinary research aimed at developing personalized approaches to CAR-T cell therapy, a rapidly advancing cancer treatment modality that can produce remarkable results in select patients, yet carries significant risks.
紐約大學(xué)坦頓應(yīng)用微生物工程實(shí)驗(yàn)室的負(fù)責(zé)人陳解釋說(shuō)，這項(xiàng)撥款將推進(jìn)跨學(xué)科研究的三個(gè)關(guān)鍵領(lǐng)域，旨在開(kāi)發(fā)個(gè)性化的car-t細(xì)胞治療方法，這是一種快速發(fā)展的癌癥治療方法，可以在選定的患者身上產(chǎn)生顯著的效果，但也具有重要風(fēng)險(xiǎn)。
The funds will support the continued development of Chen’s microfluidic “organ on a chip” systems to model disease environments and study cell interactions. This approach, which uses cells from inpidual cancer patients to create personalized, in-vitro disease models, can quickly provide key information about the potential efficacy of treatment methods—including CAR-T—against a patient’s own cancer. “Once you try a cancer therapy, it can take six months to know if it’s working,” said Chen. “By studying the interactions between tumor cells and T-cells in-vitro, we can determine if a patient is likely to be responsive in just two weeks, and our system allows us to test 10 or more treatments in parallel to find the best option.”
這些資金將支持陳的微流控“芯片上的器官”系統(tǒng)的持續(xù)發(fā)展，以模擬疾病環(huán)境和研究細(xì)胞間的相互作用這種方法利用單個(gè)癌癥患者的細(xì)胞創(chuàng)建個(gè)性化的體外疾病模型，可以快速提供關(guān)于治療方法（包括CAR-T）對(duì)患者自身癌癥的潛在療效的關(guān)鍵信息“一旦你嘗試癌癥治療，可能需要6個(gè)月才能知道它是否有效，”陳說(shuō)“通過(guò)在體外研究腫瘤細(xì)胞和T細(xì)胞之間的相互作用，我們可以確定患者是否可能在兩周內(nèi)產(chǎn)生反應(yīng)，我們的系統(tǒng)允許我們同時(shí)測(cè)試10種或更多的治療方法，以找到最佳選擇。”
Leukemia-on-a-Chip cancer microenvironment uses cells from inpidual cancer patients to create personalized, in-vitro disease models, which can quickly provide key information about the potential efficacy of treatment methods.
白血病芯片上的癌癥微環(huán)境利用單個(gè)癌癥患者的細(xì)胞創(chuàng)建個(gè)性化的體外疾病模型，可以快速提供有關(guān)治療方法潛在療效的關(guān)鍵信息。
Chen’s research, which blends engineering and medicine, is also probing the mechanical forces at play during interactions between immune cells and cancer cells, particularly during the process by which the former kills the later. Additionally, in a study published recently in the journal Advanced Materials, Chen described a novel mechanical system for measuring how local stress on a cell causes physical changes that could flag chronic diseases. He noted that there are force-mediated changes in T-cell morphology that facilitate their attachment to cancer cells, and additional forces applied as immune cells eradicate tumor cells. Through this novel investigation into the mechanobiology of CAR-T cells, Chen and his collaborators hope to illuminate, and eventually optimize, the cell mechanics involved in these interactions.
陳的研究將工程學(xué)和醫(yī)學(xué)結(jié)合在一起，同時(shí)也在探索免疫細(xì)胞和癌細(xì)胞之間的相互作用過(guò)程中，特別是前者殺死后者的過(guò)程中所發(fā)揮的機(jī)械力。此外，在最近發(fā)表在《先進(jìn)材料》雜志上的一項(xiàng)研究中，陳描述了一種新的機(jī)械系統(tǒng)，用于測(cè)量細(xì)胞局部應(yīng)力如何導(dǎo)致可能標(biāo)志慢性疾病的物理變化。他指出，在T細(xì)胞形態(tài)上有力介導(dǎo)的改變，有助于它們附著在癌細(xì)胞上，而在免疫細(xì)胞消滅腫瘤細(xì)胞時(shí)也有額外的力通過(guò)對(duì)CAR-T細(xì)胞機(jī)制生物學(xué)的新研究，陳和他的合作者希望闡明并最終優(yōu)化參與這些相互作用的細(xì)胞機(jī)制。
Finally, the grant will advance a longstanding area of Chen’s work—the development of biosensors capable of measuring chemical communication between cells. In this case, Chen aims to create sensors to detect and measure the biochemicals that facilitate communication between immune cells and tumor cells during CAR-T cell therapy.
最后，這項(xiàng)撥款將推動(dòng)陳的一項(xiàng)長(zhǎng)期工作，即開(kāi)發(fā)能夠測(cè)量細(xì)胞間化學(xué)通訊的生物傳感器在這種情況下，陳的目標(biāo)是創(chuàng)建傳感器來(lái)檢測(cè)和測(cè)量在car-t細(xì)胞治療期間促進(jìn)免疫細(xì)胞和腫瘤細(xì)胞之間通信的生化物質(zhì)。
The R35 is Chen’s second award from the National Institutes of Health. Last year Chen received the National Institute of Biomedical Imaging and Bioengineering Trailblazer R21 Award for a lab-on-a-chip system for testing immunotherapy for glioblastoma, “Engineered Glioblastoma Tumor Immunity for Personalized Immunotherapy.”
R35是陳在國(guó)立衛(wèi)生研究院獲得的第二個(gè)獎(jiǎng)項(xiàng)。去年，陳獲得了國(guó)家生物醫(yī)學(xué)成像與生物工程研究所（National Institute of Biomedical Imaging and BioEngineering Trailzer R21）頒發(fā)的膠質(zhì)母細(xì)胞瘤免疫檢測(cè)芯片系統(tǒng)“工程化膠質(zhì)母細(xì)胞瘤腫瘤免疫個(gè)性化免疫治療”獎(jiǎng)。
Earlier this month, he was one of just 12 researchers to be named a 2019 Young Innovator by the Biomedical Engineering Society.
關(guān)于紐約大學(xué)研究員獲美國(guó)國(guó)立衛(wèi)生研究院撥款，優(yōu)化CAR-T細(xì)胞癌治療!這個(gè)問(wèn)題本文的分享就到這里結(jié)束了，如果您還想了解更多相關(guān)的內(nèi)容，那么可以持續(xù)關(guān)注本頻道。
>>免費(fèi)領(lǐng)全球留學(xué)白皮書，了解各大學(xué)報(bào)考條件、費(fèi)用、開(kāi)學(xué)時(shí)間、含金量<<
HOT
1
